CPSC
PRAX icon

Carl P. Sherr & Co’s Praxis Precision Medicines PRAX Stock Holding History

Carl P. Sherr & Co’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
4,889
+3,917
+403% +$1.24M 0.69% 35
2026
Q1 		$313K Buy
972
+75
+8% +$23.2K 0.15% 103
2025
Q4 		$282K Buy
+897
New +$167K 0.13% 111

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Carl P. Sherr & Co's PRAX Position: Q2 2026 in Review

Carl P. Sherr & Co increased its Praxis Precision Medicines (PRAX) stake by 403% in Q2 2026, buying an estimated $1.24M and bringing the position to 4,889 shares worth $1.64M. The position accounts for 0.69% of the portfolio, ranked #35.

Carl P. Sherr & Co first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Carl P. Sherr & Co held 4,889 shares of Praxis Precision Medicines worth $1.64M as of Q2 2026.
  • Carl P. Sherr & Co bought 3,917 Praxis Precision Medicines shares in Q2 2026, an estimated $1.24M.
  • Praxis Precision Medicines made up 0.69% of Carl P. Sherr & Co's portfolio in Q2 2026, its #35 holding.
  • Carl P. Sherr & Co first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Carl P. Sherr & Co's 13F filing for Q2 2026, filed 3 Aug 2026.